Related Experiment Video
Updated: Jul 20, 2026
12:26
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
p21-activated kinases in cancer
Rakesh Kumar1, Anupama E Gururaj, Christopher J Barnes
1The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA. rkumar@mdanderson.org
Nature Reviews. Cancer
|May 26, 2006
Summary
p21-activated kinases (Paks) are crucial in cancer signaling and cell regulation. Targeting these kinases offers a promising therapeutic strategy for various cancers due to their role in tumor formation and invasiveness.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Kinases are vital in cellular regulation and signal transduction.
- p21-activated kinases (Paks) are serine/threonine kinases involved in oncogenic signaling pathways.
- Paks regulate cytoskeletal dynamics, cell motility, proliferation, apoptosis, and mitosis.
Purpose of the Study:
- To highlight the significance of p21-activated kinases (Paks) as therapeutic targets in cancer.
- To underscore the multifaceted roles of Paks in cancer progression.
Main Methods:
- Literature review and analysis of existing research on Pak kinases.
- Examination of Pak expression patterns in human tumors.
Main Results:
- Paks are implicated in promoting cell proliferation and invasiveness.
- Pak dysregulation contributes to tumor formation and mitotic abnormalities.
- Altered Pak expression is observed in human malignancies.
Conclusions:
- Paks play a critical role in cancer development and progression.
- The involvement of Paks in multiple cancer-associated processes makes them attractive therapeutic targets.
- Targeting Paks presents a viable strategy for novel cancer treatments.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...